Mumbai, Oct. 6 -- Through this approval, Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease.

The company's standalone net profit surged 60.1% to Rs 56.08 crore on 35.8% increase in revenue from operations to Rs 526.31 cro...